Aktuellt
SENASTE
Redeye will likely retain its positive view on Transtema following a Q1 report with comparable figures in line with our forecasts. While negatively affected by high sick leave and rising energy costs, adjusted margins held up well, and Tessta has solidly started 2022. We will likely leave our forecasts largely unchanged.
LÄS MER
